Core Insights - BD (Becton, Dickinson and Company) announced a transition plan for its CFO Chris DelOrefice, who will leave the company on December 5, 2025, with Vitor Roque appointed as interim CFO [1][2] - The company provided preliminary revenue results for the fourth quarter and full year of fiscal 2025, indicating strong growth despite challenges in certain segments [2][3] Transition of Leadership - Chris DelOrefice has been a key member of the Executive Leadership Team for four years, contributing to the BD 2025 strategy and portfolio transformation [2] - Vitor Roque, with two decades of experience at BD, will take over as interim CFO, ensuring a smooth transition [1][2] Preliminary Revenue Results - Fourth quarter preliminary revenue is approximately $5.9 billion, reflecting an estimated increase of 8.3% on a reported basis, 7.0% on a currency-neutral basis, and 3.9% on an organic basis [3][8] - Full year preliminary revenue is approximately $21.8 billion, representing an estimated increase of 8.2% on a reported basis, 7.7% on a currency-neutral basis, and 2.9% on an organic basis [3][8] Strategic Outlook - The company continues to navigate a dynamic macro environment, with strong growth in segments like BD Interventional, Advanced Patient Monitoring, and Medication Delivery Solutions [2] - BD plans to share more on its New BD strategy and expectations for fiscal 2026 in an upcoming earnings call [2] Financial Performance Metrics - The expected adjusted diluted earnings per share (EPS) for fiscal 2025 is projected to be at or above the midpoint of previously issued guidance [2] - The company emphasizes the use of non-GAAP financial measures to provide better insight into underlying operational performance [4][5]

Accessibility StatementSkip Navigation ANDOVER, Mass., Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end- stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / ...

Group 1 - Johnson & Johnson reported better-than-expected third-quarter earnings with adjusted earnings of $2.80 per share, a 15.7% increase year over year, surpassing the consensus of $2.75 [1] - The company achieved sales of $23.99 billion, reflecting a 6.8% year-over-year growth and exceeding the consensus of $23.74 billion [1] - Operational growth was recorded at 5.4%, with adjusted operational growth at 4.4% [1] Group 2 - Johnson & Johnson affirmed its fiscal year 2025 adjusted earnings guidance of $10.80-$10.90, compared to the consensus of $10.87 [2] - The company raised its sales guidance from $93.2 billion-$93.6 billion to $93.5 billion-$93.9 billion, against the consensus of $93.44 billion [2] - Johnson & Johnson announced plans to separate its Orthopedics business to enhance strategic and operational focus [2] Group 3 - Following the earnings announcement, analysts adjusted their price targets for Johnson & Johnson [3] - B of A Securities raised the price target from $198 to $204 while maintaining a Neutral rating [5] - Morgan Stanley increased its price target from $178 to $190 with an Equal-Weight rating [5] - Raymond James raised its price target from $174 to $209 while maintaining an Outperform rating [5] - Stifel increased its price target from $165 to $190 with a Hold rating [5] - Citigroup raised its price target from $213 to $215 while maintaining a Buy rating [5]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Insights - EssilorLuxottica has acquired Ikerian AG, operating under the RetinAI brand, to enhance its capabilities in AI and data management within eyecare [1][2] - The acquisition aims to strengthen the Group's med-tech journey by integrating advanced software that utilizes machine learning and computer vision to improve clinical workflows and patient care [1][3] Company Overview - RetinAI specializes in developing tools for collecting, processing, and grading large-scale retinal images and biomarker datasets, with its flagship platform, RetinAI Discovery, being FDA cleared and CE-marked [2] - The platform supports the diagnosis and monitoring of diseases such as age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy, facilitating timely and accurate decision-making in eye disease management [2] Strategic Goals - The acquisition is part of EssilorLuxottica's broader strategy to create a digitally enabled patient journey, enhancing its ecosystem that includes eyecare, diagnostics, therapeutic innovation, and surgical excellence [3] - The integration of RetinAI's AI-powered analytics is expected to transform clinical data into actionable insights, leading to faster diagnoses and improved disease monitoring [3] Leadership Perspectives - Francesco Milleri, Chairman and CEO of EssilorLuxottica, emphasized the transformative potential of this acquisition for patient care and the healthcare industry as a whole [3] - Carlos Ciller, Chairman and CEO of RetinAI/Ikerian AG, highlighted the opportunity to scale their vision of data and AI-driven patient care through EssilorLuxottica's global reach and commitment to innovation [4]

Core Insights - Abbott Laboratories' shares fell 3% following a less-than-stellar Q3 performance, with revenue rising 6.9% to $11.37 billion, missing the $11.4 billion consensus estimate [1] - Organic sales, excluding Covid testing, increased by 7.5%, surpassing the 5.9% estimate [1] - Adjusted earnings per share (EPS) rose 7.4% to $1.30, aligning with expectations [1] Financial Performance - Q3 sales in three of Abbott's four main operating segments fell short of expectations, marking the second consecutive disappointing quarter [1] - Medical Devices sales grew 12.5% organically, driven by strong performance in diabetes care and other segments [1] - Established Pharmaceuticals saw a 7.1% organic increase, while emerging markets exceeded $1 billion in sales, growing 11.1% organically [1] - Diagnostics sales declined 7.8% organically, primarily due to a nearly 28% drop in rapid diagnostics [1] Market Position and Strategy - Abbott's management tightened their full-year EPS outlook to a range of $5.12 to $5.18, consistent with consensus estimates [1] - The company continues to expect full-year organic sales growth of 7.5% to 8%, excluding Covid testing [1] - Concerns were raised regarding Abbott's exposure to China's sluggish healthcare sector, prompting discussions about portfolio adjustments [1] Segment Analysis - Nutrition sales grew 4% year over year, with adult segment sales increasing 5.4% organically, led by products like Ensure and Glucerna [2] - The point of care diagnostics segment saw nearly 8% organic growth, highlighting the adoption of new tests [1] - Abbott's ongoing litigation regarding its specialized formula for premature infants remains a concern, although management stands by the product [1]

BREAKING: Futures Rise After Volatile, Mixed Market Session Abbott stock skidded early Wednesday after the health giant reported adjusted earnings of $1.30 per share on $11.37 billion in third-quarter sales. On average, analysts polled by FactSet expected Abbott Laboratories (ABT) to earn $1.30 per share and report $11.39 billion in sales. Leerink Partners analyst Mike Kratky noted strength in the medtech division helped offset weakness in diagnostics, nutrition and established pharmaceuticals. During the y ...

Brossard, Quebec--(Newsfile Corp. - October 15, 2025) - Diagnos Inc. (TSXV: ADK) (OTCQB: DGNOF) (FSE: 4D4A) ("DIAGNOS" or the "Corporation"), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), is pleased to announce it will be presenting at the Centurion One Capital 3rd Annual Bahamas Summit, a two-day invitation only event taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 28th to Wednesday, October 29th, 2025, i ...

Core Insights - Intuitive Surgical's Ion platform is emerging as a strategic asset in the rapidly growing ambulatory surgical centers (ASCs) segment, capitalizing on the shift of procedures from hospitals to outpatient settings, particularly in minimally invasive diagnostics [1][5] Group 1: Ion Platform Performance - Ion, designed for minimally invasive lung biopsy and diagnostics, experienced a 52% year-over-year increase in procedures in Q2 2025, with an 8% rise in utilization per installed system [2][11] - The demand for Ion is driven by the preference of payors and providers for ASCs due to their efficiency and cost-effectiveness, alongside the increasing prevalence of pulmonary nodules and lung cancer screening programs [2][4] Group 2: Strategic Positioning - Management's strategy involves positioning newer platforms like Ion for high-volume centers while transitioning legacy systems into ASCs, allowing for deeper hospital presence and new growth opportunities [3][4] - This dual approach enables hospitals to utilize the latest systems in flagship locations while deploying older systems in satellite ASCs, thus capturing outpatient volume without significant capital strain [4] Group 3: Market Potential and Competitive Landscape - The key question for investors is whether Ion's growth can significantly impact Intuitive Surgical's revenue mix, as it currently has under 1,000 installed systems, indicating early adoption with substantial growth potential [5] - Other medtech companies, such as Boston Scientific and Becton, Dickinson & Company, are also targeting ASCs with tailored solutions, indicating a competitive landscape for outpatient surgical technologies [6][10]

Core Insights - Abbott Laboratories reported adjusted earnings of $1.30 per share on $11.37 billion in third-quarter sales, slightly missing sales expectations of $11.39 billion [1][2] - The company reaffirmed its sales guidance for 7.5% to 8% organic sales growth for the year, excluding the impact of Covid tests, and narrowed its earnings outlook to a range of $5.12 to $5.18 per share [2] Financial Performance - In the same quarter last year, Abbott earned $1.21 per share on $10.64 billion in sales, indicating a year-over-year earnings increase of approximately 7.4% and sales growth of about 6.9% [2] - Analysts projected an average earnings per share of $5.15 and total sales of $44.69 billion for the year [2] Stock Market Reaction - In premarket trading, Abbott's stock fell nearly 3% to $128.94, breaking out of a cup-with-handle base with a buy point at $134.71 [3] - The stock is currently below the 5% chase zone and facing resistance at its 50-day moving average [3]